MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
The company is bringing precision therapies for gynaecological cancers
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
